english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Not that common

 Editorial  Independence. Transparency. Two words that are overused, especially in the field of health care. Prescrire takes transparency as far as publishing its financial statement every year. Which is not that common.
1 June 2022

Prescrire's finances: 2021 annual report

Association Mieux Prescrire (AMP), the legal entity responsible for Prescrire's publications, is a non-profit organisation that makes its accounts public every year. The annual report for 2021 appears in the June issue of Prescrire International, and online here.
1 June 2022

Messenger RNA covid-19 vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°) during pregnancy

in focusWhat main points should pregnant women be aware of in order to make informed decisions about covid-19 vaccination?
1 June 2022

Peanut allergy: peanut-avoidant diet and access to adrenaline injector pens

For patients with peanut allergy, complete elimination of peanuts from the diet and access to adrenaline pens is a better option than oral desensitisation.
1 June 2022

Strategic choices

 Editors' Opinion  Choosing certain endpoints in clinical trials can mask outcomes that really matter to patients. It is certainly not a strategy that ensures high-quality treatments that improve patient care.
1 June 2022

Depression: possible increase in the risk of suicide with esketamine (Spravato°)

Clinical trials and pharmacovigilance data show a possible increase in the risk of suicide with esketamine (Spravato°), a drug authorised for use in "treatment-resistant" depression and "psychiatric emergencies".
1 June 2022

"Preventing Overdiagnosis 2022": an international conference to be held in Calgary, 9-12 June

The not-for-profit group "Preventing Overdiagnosis", dedicated to "winding back the harms of too much medicine", will be holding its 2022 conference in Calgary, Canada.
10 May 2022

Ozanimod (Zeposia°) in multiple sclerosis. As ineffective and probably as toxic as fingolimod

FEATURED REVIEW This immunosuppressant has been authorised in the European Union for use in adults with a relapsing-remitting form of multiple sclerosis. Is ozanimod more effective than an interferon beta at reducing the number of relapses and slowing the progression of disability? And what are its adverse effects?
Full review (3 pages) available for download by subscribers.
1 May 2022

In the May issue of Prescrire International: Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer

FREE DOWNLOAD A solution for subcutaneous injection containing a fixed-dose combination of these two anti-HER2 monoclonal antibodies has been authorised in the EU. How do Prescrire's editors rate this combination in its new form?
Full text available for free download.
1 May 2022

The EMA is withholding too much information

 Editorial  Transparency is a requirement for better and safer patient care. There is no valid reason to hide information about clinical trials, their methodology or their results, or evaluation data obtained on drugs after their market introduction, particularly data on adverse effects.
1 May 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90